NASDAQ: BIIB ) PD-related tickers: (NASDAQ: ACOR ) (Pending: CVTS ) (NASDAQ: ACAD ) ( OTCQX:CYNAF ) (NASDAQ: IPXL ) ( OTCQB:TTNP ) ( OTCQB:SGTH ) (NYSE: TEVA ) (NASDAQ: ADMS ) (NASDAQ: PRAN ) (NASDAQ: CHTP ) (NASDAQ: PRTA
Oct 9 (Reuters) - Impax Laboratories Inc said it was on the hunt for further deals - and would consider a so-called "tax inversion" transaction - after its acquisition of two privately held...
Top 10 Gainers: LAKE +44% . DYNT +22% . PRTS +19% . RT +16% . GTIV +16% . APT +14% . EMAN +14% . ESI +12% . IPXL +11% . RENT +11% . Top 10 Losers: EOPN -28% . ARCW -24% . KFX -20% . EXXI -17% . OTCQB:VPCO -16% . SZYM -15
Impax Laboratories ( IPXL +13.9% ) acquires Tower Holdings, including operating subsidiaries CorePharma LLC and Amedra Pharmaceuticals LLC, and Lineage
Oct 9 (Reuters) - Impax Laboratories Inc said it bought two privately held drugmakers for $700 million to gain access to seven generic drugs.
Impax Laboratories ( IPXL -1% ) will report Q3 results on November 4 before the open. The conference call will begin at 8:30 am ET. Consensus view is EPS of $0.29 on revenues of $149M. Post your comment!
July 29 (Reuters) - Impax Laboratories Inc said the U.S. Food and Drug Administration issued "certain observations" after an inspection of the company's manufacturing plant in Taiwan.
(Reuters) - Shares of Impax Laboratories Inc fell as much as 10 percent on Tuesday, after U.S. health regulators denied approval to the company's Parkinson's drug and asked for a reinspection of its...
(Reuters) - Impax Laboratories Inc said it received a warning letter from U.S. health regulators on deficient sampling and testing of drugs at its Hayward, California-based plant, sending the...
competition until late 2011, thanks to several deals with Teva TEVA, Sandoz (a unit of Novartis NVS), Mylan MYL, and Impax IPXL . By paying the generic companies to delay competition, Medicis has lengthened the runway for Solodyn. The firm may have bought